The Vector Labs are structured and organized under a new paradigm for Vector Core operations that is designed to provide investigators with a single source that can supply their vector needs throughout the development of the research programs. The labs utilize an integrated systems approach to speed the flow of vector technologies and information. These systems are designed to provide comprehensive resources to investigators so they can avoid many of the common pitfalls and delays that occur during the translational research period. These pitfalls and delays are caused when a specific vector-disease approach must transition from a basic research environment into the highly regulated and controlled processes of final preclinical safety testing and human clinical trials. The UNC Vector Labs will support MTCC investigators by providing expertise with vector design, construction, and development as well as by providing investigators with the viral vector reagents themselves. Investigators will be able to select the optimal type of viral platform (adenoviral, AAV, lentiviral, retroviral, PIV, cell-based, or plasmid) for the specific research in which they are involved. Investigators can also select from a range of standard quality grades (research, preclinical, or clinical), or can custom design intermediate grades as necessary. The combined staff at the Vector Labs and the Gene Therapy Center have prior experience in bringing to clinical trials virtually all the major viral platforms. Investigators will be able to utilize this experience to aid in creating drug development templates as their research progresses into the clinical arena.
The Vector Core will provide a broad range of services that will benefit public health. Its foremost mission is to provide gene transfer vectors that will treat people with genetic diseases. An important parallel mission is to develop gene transfer vectors that may aid in immunization of the general population to a variety of communicable diseases.
|Ostrowski, L E; Yin, W; Patel, M et al. (2014) Restoring ciliary function to differentiated primary ciliary dyskinesia cells with a lentiviral vector. Gene Ther 21:253-61|
|Morales Johansson, Helena; Newman, Donna R; Sannes, Philip L (2014) Whole-genome analysis of temporal gene expression during early transdifferentiation of human lung alveolar epithelial type 2 cells in vitro. PLoS One 9:e93413|
|Henderson, Ashley G; Ehre, Camille; Button, Brian et al. (2014) Cystic fibrosis airway secretions exhibit mucin hyperconcentration and increased osmotic pressure. J Clin Invest 124:3047-60|
|Saini, Yogesh; Dang, Hong; Livraghi-Butrico, Alessandra et al. (2014) Gene expression in whole lung and pulmonary macrophages reflects the dynamic pathology associated with airway surface dehydration. BMC Genomics 15:726|
|Esther Jr, Charles R; Boucher, Richard C; Johnson, M Ross et al. (2014) Airway drug pharmacokinetics via analysis of exhaled breath condensate. Pulm Pharmacol Ther 27:76-82|
|Cholon, Deborah M; Quinney, Nancy L; Fulcher, M Leslie et al. (2014) Potentiator ivacaftor abrogates pharmacological correction of ?F508 CFTR in cystic fibrosis. Sci Transl Med 6:246ra96|
|Tadokoro, Tomomi; Wang, Yang; Barak, Larry S et al. (2014) IL-6/STAT3 promotes regeneration of airway ciliated cells from basal stem cells. Proc Natl Acad Sci U S A 111:E3641-9|
|Bove, Peter F; Dang, Hong; Cheluvaraju, Chaitra et al. (2014) Breaking the in vitro alveolar type II cell proliferation barrier while retaining ion transport properties. Am J Respir Cell Mol Biol 50:767-76|
|Guo, Xueliang; Zheng, Shuo; Dang, Hong et al. (2014) Genome reference and sequence variation in the large repetitive central exon of human MUC5AC. Am J Respir Cell Mol Biol 50:223-32|
|Schwab, Ute; Abdullah, Lubna H; Perlmutt, Olivia S et al. (2014) Localization of Burkholderia cepacia complex bacteria in cystic fibrosis lungs and interactions with Pseudomonas aeruginosa in hypoxic mucus. Infect Immun 82:4729-45|
Showing the most recent 10 out of 57 publications